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    We insti，lled FT 207 （Nf一（12－tetra－hydrourhcil－5－fluorouracil） 2000－4000 mg （20－40 ml） intra－
vesically in 24 cases of bladder tumQr twice a week for a total of I O inst’illations．
   The anti－tumor effect of this preparation was studied in 6 cases which were treated for the first
time．
   As a result， there were temporary clearance oftumor in 1 case， regressien in 2 cases， and 1 unchanged
case， but in no case was complete clearance observed．
   As to the effect to prevent recurrence， recurrence was・ noted in 8 out of 16 cases with intravesical
insti11ation）ofF［r 207 alone and 6 out Qf 8 cases with combinatienal use of60Co irradiation ofthe bladder
and pelvic region and intravesical instillation of FT 207 during a 23－month observation． lrritative
symptoms」of the．bladd．er leukopenia and other side－effects were not observed du血g the period of
of intravesical instillation．
   The anti－tumor effect and recurrence－preven．ting effect of intravesical instillation of FT 207 appear
to be lower than those of other anti－cancer drugs．
   HQwever， it should be noted that the lymph node levels of FT’207， when instilled intravesically，
are higher thau those of ether anti－cancer drygs． lf the meFhod of administration is studied durther，
this prepar4ti6n is expected tg ．exert effect on infiltrative tumor．
















  投与方法は FT207，2000～4000mg（20～．40ml）を















                    1 回年齢 性  大きさ  数 浸潤性grade stage                   投与量
投与     保時        効 果  total     留間回数
50 （F） 半米粒大 3ケ  非
7ア （M） 小豆大  ．単   非
64 （M） 小豆大  3ケ  非
ア2 （F） 半米粒大 2ケ  非
75 （F＞ 米粒大  単   非






  2000     2／WA －4000mg
o 4000mg 2fw
O 4000mg 2／w
  2000     2／Wo －4000mg
O 4000mg 2／W
40 1h 一時的消失
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 不変  消失  消失  増加・増大





















transitional cell carcinoma gradc I， s’tage Oであっ
た。
症例3（Fig．3）．プ2歳，女．
 1975年10月24日，TUR－Bt（transitional cell carci－










     半米粒大        半米粒大
      2ケ            1ケ
F丁＿207           4000mg           4000mg
           1ケ消失        ．不変
    Fig． 2． Transitional cell carcinoma grade 1 stage O
ワ7．7．9







     小豆大      ．  半米粒大
      1ケ            1ケ
FT－207 4000Fng 4000mg           縮  少         不  変




carcinoma， grade II， stage Oであった．
 以上，FT207の膀注による1時的な抗腫瘍効果（消
失または縮小）例を挙げたが，恒久的効果例はなかっ
た．無効の3例はtransitional ccll carcinoma grade






grade I～II stage O～Aが16例， gradc III～IV，






































thio－TEPA 60一一77％‘，7一’9）， actinomycin D 25％8）， 5－
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